Alpha Lipoic Acid Supplementation and Metabolic Syndrome

Metabolic Syndrome Clinical Trial

Official title:

Assessment of the Effect of Alpha Lipoic Acid Supplementation on Inflammatory Factors, Insulin Resistance, Glycemic Control and Anthropometric Indices in Patients With Metabolic Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03589690
• Other study ID #: IR.IAU.SRB.REC.1396.82
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 25, 2018
• Est. completion date: July 25, 2019

Study information

• Verified date: July 2018
• Source: Science & Research Islamic Azad University Branch Khozestan
• Contact: Behnood Abbasi, Ph.D.
• Phone: 44864929
• Email: abbasi.b[@]srbiau.ac.ir
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metabolic syndrome is a collection of metabolic disorders. Abdominal obesity, dyslipidemia, reduced levels of high-density lipoprotein cholesterol, increased levels of serum triglyceride, insulin resistance are among the risk factors for metabolic syndrome and it has a global prevalence of 10 - 50 %.

Alpha-lipoic acid or thioctic acid is an antioxidant that may have effects on inflammatory pathways, glucose control indicators, blood pressure, lipid profiles, body weight, fat mass, and food intake regulation.

This study will be conducted as a parallel randomized double-blind clinical trial. In this study, 44 patients will be enrolled from endocrine and metabolism center of Shariati Hospital where their metabolic syndrome was diagnosed by an endocrinologist. At the beginning of the study written a self -administration will be taken from all patients.

In this study, patient will be randomly divided into two groups, each will be received supplement or placebo for 12 weeks. 22 of patients will be consume 600 mg Alpha lipoic acid for 12 weeks and 22 of patients will be consume 600 mg placebo (starch-filled) capsules daily. Both supplementation and placebo are provided from "Sepehr Drug and Treatment" company. Before the study, containers will be coded as A and B by a person other than the study researchers according to concealment rules. Physical activity information will be collected using short-IPAQ (International Physical Activity Questionnaire) and demographic information through a general information questionnaire. In order to evaluate dietary intake of patients in terms of energy(kcal/(day), carbohydrate(gr/day), protein(gr/day), fat intake(gr/day), SFA (Saturated fatty acids) (gr/day), MUFA (Monounsaturated fatty acids) (gr/day), PUFA (Polyunsaturated fatty acids)(gr/day), Vitamin E(mg/day), Vitamin C(mg/day), Beta-carotene(mg/day) and Sodium intake (mg/day), 24-hr recalls will be completed by interviewing the patient for 3 days (two normal days and a weekend day). Weight will be measured with the minimum dress and without shoes by using a digital balance scale of 100 grams and height will be measured without shoes by meters mounted to the wall with an accuracy of 0.1 centimeters. Then the body mass index will be calculated by dividing the weight (kg) by the square of the height (m), waist circumference will be measured in the narrowest area between the lowest lumbar spine and the iliac bone (cm), systolic and diastolic blood pressure will be measured after 15 minutes of rest, twice using the mercuric barometric measure and the mean will be reported as individual blood pressure. The blood sample will be taken after 12 hours of overnight fasting in two groups for measuring fasting blood glucose(mg/dL), lipid profile(mg/dL), glycosylated hemoglobin(percentage), serum insulin concentration (uIU/ml) ,TAC (Total antioxidant capacity) (umol/L), CRP (C-reactive protein) (ng/ml) and TNF-a (Tumor necrosis factor-a ) (pg/ml)and will be used the HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) formula to determine insulin resistance. All these steps will be completed at the start and end of the study. At the end of the study, counting the remaining capsules, the patient's compliance rate will be evaluated, and patients who have not consumed less than 90% of their capsules will be excluded from the analysis.

Description:

This is a randomized, double-blind, parallel clinical trial of lipoic acid for inflammatory factors, insulin resistance, glycemic control and anthropometric indices in patients with metabolic syndrome. patients are randomly shared into two groups and received 600 mg supplemental and placebo for 12 weeks, Then the body mass index, waist circumference, systolic and diastolic blood pressure, FBS (fasting blood sugar), lipid profile ,HbA1C, serum insulin concentration, TAC, CRP and TNF-a , Insulin resistance are measured ;All these steps will be done at the start and end of the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: July 25, 2019
• Est. primary completion date: April 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. having 3 criteria or more of the Metabolic Syndrome criteria presented in NCEP:ATP III (National Cholesterol Education Panel : Adult Treatment Panel III)

2. Adults(18-60 y)

3. PO (not fasting) and oral feeding ability

4. full person`s willingness to cooperate in the project

5. Lack of digestive problems

6. Not pregnancy and Lactation

7. No history of myocardial infarction and brain stroke in the past year

8. Diabetes controlled

9. Lack of any Cardiovascular disease

Exclusion Criteria

1. Pregnancy

2. Cardiovascular and brain stroke

3. Diagnosis of uncontrolled diabetes during research

4. Have any need for medication that may interfere in the study process

5. Unwillingness to continue the cooperation of each research unit

6. Death of each research unit

7. Consume less than %90 of the number of supplement and placebo to be eaten

8. Involvement in other clinical trial in last three months

9. Menopause

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Dietary Supplement:
• Alpha lipoic acid
22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
• Placebo
Participants will be supplemented with 600 mg/day placebo (Starch).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dr. B.Abbasi

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline of CRP	Serum C-reactive protein (ng/ml)	Baseline and 12 weeks after
Secondary	Change from baseline of Tnf-a	Serum tumor necrosis factor-a (pg/ml)	Baseline and 12 weeks after
Secondary	Change from baseline of FBS	Fasting blood glucose concentration (mg/dl)	Baseline and 12 weeks after
Secondary	Change from baseline of Triglyceride	Serum TG (triacylglycerol) concentration (mg/dl)	Baseline and 12 weeks after
Secondary	Change from baseline of total cholesterol	Serum TC (total cholesterol) concentration (mg/dl)	Baseline and 12 weeks after
Secondary	Change from baseline of LDL-Cholesterol	Serum LDL concentration (mg/dl)	Baseline and 12 weeks after